Johnson & Johnson Restructures Supply Chain with Facility Exits
Johnson & Johnson is restructuring its supply chain, primarily within the innovative medicine segment. The initiative began in fiscal Q2 2026 and involves exiting certain manufacturing locations to streamline operations. While specific facilities have not been disclosed, the company expects the project to conclude by the end of fiscal year 2029. The estimated total cost for restructuring is up to $750 million, with charges related to site exits, decommissioning, and asset impairments. In Q2 alone, Johnson & Johnson incurred $200 million in expenses, largely from asset impairments. Despite these costs, the company continues investing heavily in domestic production. Johnson & Johnson recently announced a $1 billion investment for a contact lens manufacturing plant in Jacksonville, Florida, over two years and previously outlined plans to invest $55 billion in U.S. production by 2030.
Topics: domestic investment manufacturing exit restructuring